A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

Jacob P. Lalezari, Joseph J. Eron, Margrit Carlson, Calvin Cohen, Edwin DeJesus, Roberto C. Arduino, Joel E. Gallant, Paul Volberding, Robert L. Murphy, Fred Valentine, Emily L. Nelson, Prakash R. Sista, Alex Dusek, J. Michael Kilby

Research output: Contribution to journalArticle

Abstract

Objectives: The primary objective was to determine the long-term safety of the subcutaneous self-administration of enfuvirtide. Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen. Methods: A multicenter 48-week uncontrolled open-label rollover study was conducted on 71 HIV-infected adults recruited from previous enfuvirtide clinical trials. Patients with extensive previous use of protease and reverse transcriptase inhibitors received a twice-daily dose of 50 mg enfuvirtide subcutaneously (45 mg deliverable) combined with two or more antiretroviral drugs selected for each individual, guided by resistance testing and previous treatment history. Results: The mean baseline plasma HIV-RNA level was 4.81 log10 copies/ml and the mean CD4 cell count was 134.8 cells/μl. The majority (86.9%) of treatment-emergent adverse events were grade 2 or less in severity. Injection site reactions were common, but no patients discontinued treatment. A mean HIV-RNA change of -1.33 log10 was achieved within 14 days of treatment initiation. At week 48, approximately one-third of all patients in the intent-to-treat population maintained significant suppression of plasma HIV RNA, with either less than 400 copies/ml or more than a 1.0 log10 decline from baseline. The mean gain in absolute CD4 cell counts at 48 weeks was 84.9 cells/μl. Trough plasma concentrations of enfuvirtide were consistently higher than target concentrations. Conclusion: Self-administration of enfuvirtide is not associated with unexpected toxicities for up to one year, and combined with oral antiretroviral drugs was associated with a significant decrease in HIV RNA and an increase in CD4 cell counts.

Original languageEnglish (US)
Pages (from-to)691-698
Number of pages8
JournalAIDS
Volume17
Issue number5
DOIs
StatePublished - Mar 28 2003

Fingerprint

Antiviral Agents
Safety
HIV
CD4 Lymphocyte Count
RNA
Self Administration
Therapeutics
Reverse Transcriptase Inhibitors
enfuvirtide
Clinical Studies
Pharmaceutical Preparations
Peptide Hydrolases
Pharmacokinetics
History
Clinical Trials
Injections
Population

Keywords

  • Antiretroviral therapy
  • Enfuvirtide
  • Fusion inhibitor
  • T-20

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., DeJesus, E., Arduino, R. C., ... Kilby, J. M. (2003). A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS, 17(5), 691-698. https://doi.org/10.1097/00002030-200303280-00007

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. / Lalezari, Jacob P.; Eron, Joseph J.; Carlson, Margrit; Cohen, Calvin; DeJesus, Edwin; Arduino, Roberto C.; Gallant, Joel E.; Volberding, Paul; Murphy, Robert L.; Valentine, Fred; Nelson, Emily L.; Sista, Prakash R.; Dusek, Alex; Kilby, J. Michael.

In: AIDS, Vol. 17, No. 5, 28.03.2003, p. 691-698.

Research output: Contribution to journalArticle

Lalezari, JP, Eron, JJ, Carlson, M, Cohen, C, DeJesus, E, Arduino, RC, Gallant, JE, Volberding, P, Murphy, RL, Valentine, F, Nelson, EL, Sista, PR, Dusek, A & Kilby, JM 2003, 'A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy', AIDS, vol. 17, no. 5, pp. 691-698. https://doi.org/10.1097/00002030-200303280-00007
Lalezari, Jacob P. ; Eron, Joseph J. ; Carlson, Margrit ; Cohen, Calvin ; DeJesus, Edwin ; Arduino, Roberto C. ; Gallant, Joel E. ; Volberding, Paul ; Murphy, Robert L. ; Valentine, Fred ; Nelson, Emily L. ; Sista, Prakash R. ; Dusek, Alex ; Kilby, J. Michael. / A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. In: AIDS. 2003 ; Vol. 17, No. 5. pp. 691-698.
@article{b77627287acc4cf199f8d8e3667736bd,
title = "A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy",
abstract = "Objectives: The primary objective was to determine the long-term safety of the subcutaneous self-administration of enfuvirtide. Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen. Methods: A multicenter 48-week uncontrolled open-label rollover study was conducted on 71 HIV-infected adults recruited from previous enfuvirtide clinical trials. Patients with extensive previous use of protease and reverse transcriptase inhibitors received a twice-daily dose of 50 mg enfuvirtide subcutaneously (45 mg deliverable) combined with two or more antiretroviral drugs selected for each individual, guided by resistance testing and previous treatment history. Results: The mean baseline plasma HIV-RNA level was 4.81 log10 copies/ml and the mean CD4 cell count was 134.8 cells/μl. The majority (86.9{\%}) of treatment-emergent adverse events were grade 2 or less in severity. Injection site reactions were common, but no patients discontinued treatment. A mean HIV-RNA change of -1.33 log10 was achieved within 14 days of treatment initiation. At week 48, approximately one-third of all patients in the intent-to-treat population maintained significant suppression of plasma HIV RNA, with either less than 400 copies/ml or more than a 1.0 log10 decline from baseline. The mean gain in absolute CD4 cell counts at 48 weeks was 84.9 cells/μl. Trough plasma concentrations of enfuvirtide were consistently higher than target concentrations. Conclusion: Self-administration of enfuvirtide is not associated with unexpected toxicities for up to one year, and combined with oral antiretroviral drugs was associated with a significant decrease in HIV RNA and an increase in CD4 cell counts.",
keywords = "Antiretroviral therapy, Enfuvirtide, Fusion inhibitor, T-20",
author = "Lalezari, {Jacob P.} and Eron, {Joseph J.} and Margrit Carlson and Calvin Cohen and Edwin DeJesus and Arduino, {Roberto C.} and Gallant, {Joel E.} and Paul Volberding and Murphy, {Robert L.} and Fred Valentine and Nelson, {Emily L.} and Sista, {Prakash R.} and Alex Dusek and Kilby, {J. Michael}",
year = "2003",
month = "3",
day = "28",
doi = "10.1097/00002030-200303280-00007",
language = "English (US)",
volume = "17",
pages = "691--698",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

AU - Lalezari, Jacob P.

AU - Eron, Joseph J.

AU - Carlson, Margrit

AU - Cohen, Calvin

AU - DeJesus, Edwin

AU - Arduino, Roberto C.

AU - Gallant, Joel E.

AU - Volberding, Paul

AU - Murphy, Robert L.

AU - Valentine, Fred

AU - Nelson, Emily L.

AU - Sista, Prakash R.

AU - Dusek, Alex

AU - Kilby, J. Michael

PY - 2003/3/28

Y1 - 2003/3/28

N2 - Objectives: The primary objective was to determine the long-term safety of the subcutaneous self-administration of enfuvirtide. Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen. Methods: A multicenter 48-week uncontrolled open-label rollover study was conducted on 71 HIV-infected adults recruited from previous enfuvirtide clinical trials. Patients with extensive previous use of protease and reverse transcriptase inhibitors received a twice-daily dose of 50 mg enfuvirtide subcutaneously (45 mg deliverable) combined with two or more antiretroviral drugs selected for each individual, guided by resistance testing and previous treatment history. Results: The mean baseline plasma HIV-RNA level was 4.81 log10 copies/ml and the mean CD4 cell count was 134.8 cells/μl. The majority (86.9%) of treatment-emergent adverse events were grade 2 or less in severity. Injection site reactions were common, but no patients discontinued treatment. A mean HIV-RNA change of -1.33 log10 was achieved within 14 days of treatment initiation. At week 48, approximately one-third of all patients in the intent-to-treat population maintained significant suppression of plasma HIV RNA, with either less than 400 copies/ml or more than a 1.0 log10 decline from baseline. The mean gain in absolute CD4 cell counts at 48 weeks was 84.9 cells/μl. Trough plasma concentrations of enfuvirtide were consistently higher than target concentrations. Conclusion: Self-administration of enfuvirtide is not associated with unexpected toxicities for up to one year, and combined with oral antiretroviral drugs was associated with a significant decrease in HIV RNA and an increase in CD4 cell counts.

AB - Objectives: The primary objective was to determine the long-term safety of the subcutaneous self-administration of enfuvirtide. Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen. Methods: A multicenter 48-week uncontrolled open-label rollover study was conducted on 71 HIV-infected adults recruited from previous enfuvirtide clinical trials. Patients with extensive previous use of protease and reverse transcriptase inhibitors received a twice-daily dose of 50 mg enfuvirtide subcutaneously (45 mg deliverable) combined with two or more antiretroviral drugs selected for each individual, guided by resistance testing and previous treatment history. Results: The mean baseline plasma HIV-RNA level was 4.81 log10 copies/ml and the mean CD4 cell count was 134.8 cells/μl. The majority (86.9%) of treatment-emergent adverse events were grade 2 or less in severity. Injection site reactions were common, but no patients discontinued treatment. A mean HIV-RNA change of -1.33 log10 was achieved within 14 days of treatment initiation. At week 48, approximately one-third of all patients in the intent-to-treat population maintained significant suppression of plasma HIV RNA, with either less than 400 copies/ml or more than a 1.0 log10 decline from baseline. The mean gain in absolute CD4 cell counts at 48 weeks was 84.9 cells/μl. Trough plasma concentrations of enfuvirtide were consistently higher than target concentrations. Conclusion: Self-administration of enfuvirtide is not associated with unexpected toxicities for up to one year, and combined with oral antiretroviral drugs was associated with a significant decrease in HIV RNA and an increase in CD4 cell counts.

KW - Antiretroviral therapy

KW - Enfuvirtide

KW - Fusion inhibitor

KW - T-20

UR - http://www.scopus.com/inward/record.url?scp=0037471311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037471311&partnerID=8YFLogxK

U2 - 10.1097/00002030-200303280-00007

DO - 10.1097/00002030-200303280-00007

M3 - Article

C2 - 12646792

AN - SCOPUS:0037471311

VL - 17

SP - 691

EP - 698

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 5

ER -